Vetmedin is a drug owned by BOEHRINGER LNGELHEIM ANIMAL HEALTH USA, INC. It is protected by 3 US drug patents filed from 2025 to 2027. Out of these, 1 patent is active and 2 patents have expired. Details of Vetmedin’s patents and their expiration are given below.
| Drug Patent Number | Drug Patent Expiry | Status |
|---|---|---|
 | ||
| US8846680 | 04 Mar, 2025 | Expired |
Exclusivity Information
Vetmedin holds 1 exclusivity out of which 1 has expired. Details of Vetmedin's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| NCE | Apr 30, 2012 |
Vetmedin Petitions
Details of Vetmedin's suitability petitions are listed below.
| Petitioner | Action | Date of Action | Description |
|---|---|---|---|
 | |||
| Noble Pharma, LLC | Approved | 14 Mar, 2023 | The proposed change is in dosage form from a compressed, flavored, and half-scored hard chewable tablet to an extruded, chicken liver-flavored, and half-scored soft chewable tablet . |
| Felix Pharmaceuticals Pvt. Ltd. | Approved | 22 Nov, 2021 | The proposed change is for an oral suspension ; the RLNAD is approved as scored, chewable tablets in 1.25 mg, 2.5 mg, 5 mg, and 10 mg tablet strengths. |
| Norbrook Laboratories Limited | Approved | 14 Dec, 2018 | The proposed change is for an oral solution ; the RLNAD is approved as chewable tablets in 1.25 mg, 2.5 mg, 5 mg, and 10 mg tablet strengths. |
| Felix Pharmaceuticals Pvt. Ltd. | Approved | 13 Jun, 2018 | The proposed change is from a compressed tablet to a soft chewable tablet. |
| Piedmont Animal Health | Approved | 26 Aug, 2014 | The generic product will differ in dosage form. The RLNAD is approved as a compressed, hard, chewable tablet. The proposed dosage form is a soft chewable tablet. |
| Dechra, Ltd. | Approved | 05 Feb, 2013 | The generic product will differ in concentration. The RLNAD is approved in tablet strengths of 1.25, 2.5, and 5 mg, whereas the generic product proposes to add an additional 10 mg tablet. |
| Center for Regulatory Services, Inc. | Approved | 08 Nov, 2012 | The generic product will differ in concentration. The RLNAD is approved in tablet strengths of 1.25, 2.5, and 5 mg, wherease the generic product proposes to add an additional 10 mg tablet. |
| Lachman Consultant Service, Inc. | Approved | 22 Feb, 2010 | |
About Vetmedin
Vetmedin is a drug
owned by BOEHRINGER LNGELHEIM ANIMAL HEALTH USA, INC.
Vetmedin uses
Pimobendan as the active
ingredient.
Active Ingredient:
Vetmedin uses
Pimobendan as the active ingredient.
Check out other Drugs and Companies using
Pimobendan ingredient.